nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—PTGS2—colon cancer	0.294	1	CbGaD
Celecoxib—ABCC4—Fluorouracil—colon cancer	0.0902	0.305	CbGbCtD
Celecoxib—ABCC4—Methotrexate—colon cancer	0.0497	0.168	CbGbCtD
Celecoxib—ALB—Irinotecan—colon cancer	0.0348	0.118	CbGbCtD
Celecoxib—ALB—Fluorouracil—colon cancer	0.0334	0.113	CbGbCtD
Celecoxib—CYP2C9—Capecitabine—colon cancer	0.0304	0.103	CbGbCtD
Celecoxib—ALB—Methotrexate—colon cancer	0.0184	0.0624	CbGbCtD
Celecoxib—CYP2C9—Fluorouracil—colon cancer	0.018	0.061	CbGbCtD
Celecoxib—CYP3A4—Irinotecan—colon cancer	0.0109	0.0369	CbGbCtD
Celecoxib—CYP3A4—Vincristine—colon cancer	0.00954	0.0323	CbGbCtD
Celecoxib—ORM1—bile—colon cancer	0.00674	0.0893	CbGeAlD
Celecoxib—PDPK1—embryo—colon cancer	0.00368	0.0488	CbGeAlD
Celecoxib—MAPK14—blood vessel—colon cancer	0.0033	0.0437	CbGeAlD
Celecoxib—CA9—gall bladder—colon cancer	0.00319	0.0422	CbGeAlD
Celecoxib—PDPK1—renal system—colon cancer	0.00279	0.0369	CbGeAlD
Celecoxib—PDPK1—lymphoid tissue—colon cancer	0.00231	0.0307	CbGeAlD
Celecoxib—PDPK1—digestive system—colon cancer	0.00229	0.0303	CbGeAlD
Celecoxib—PDPK1—vagina—colon cancer	0.00202	0.0267	CbGeAlD
Celecoxib—MAPK14—embryo—colon cancer	0.00197	0.0261	CbGeAlD
Celecoxib—ORM1—gall bladder—colon cancer	0.00187	0.0248	CbGeAlD
Celecoxib—PDPK1—liver—colon cancer	0.0017	0.0226	CbGeAlD
Celecoxib—ALB—gall bladder—colon cancer	0.00164	0.0217	CbGeAlD
Celecoxib—MAPK14—epithelium—colon cancer	0.00161	0.0213	CbGeAlD
Celecoxib—CA5A—liver—colon cancer	0.0016	0.0212	CbGeAlD
Celecoxib—MAPK14—smooth muscle tissue—colon cancer	0.00155	0.0205	CbGeAlD
Celecoxib—MAPK14—renal system—colon cancer	0.00149	0.0198	CbGeAlD
Celecoxib—PDPK1—lymph node—colon cancer	0.00131	0.0173	CbGeAlD
Celecoxib—Etoricoxib—PTGS2—colon cancer	0.00127	1	CrCbGaD
Celecoxib—CA9—digestive system—colon cancer	0.00125	0.0166	CbGeAlD
Celecoxib—MAPK14—lymphoid tissue—colon cancer	0.00124	0.0164	CbGeAlD
Celecoxib—MAPK14—digestive system—colon cancer	0.00122	0.0162	CbGeAlD
Celecoxib—CA2—gall bladder—colon cancer	0.00121	0.016	CbGeAlD
Celecoxib—CA12—renal system—colon cancer	0.00113	0.015	CbGeAlD
Celecoxib—MAPK14—bone marrow—colon cancer	0.00113	0.0149	CbGeAlD
Celecoxib—MAPK14—vagina—colon cancer	0.00108	0.0143	CbGeAlD
Celecoxib—PTGS2—endothelium—colon cancer	0.00103	0.0136	CbGeAlD
Celecoxib—PTGS2—blood vessel—colon cancer	0.000949	0.0126	CbGeAlD
Celecoxib—CA12—digestive system—colon cancer	0.000927	0.0123	CbGeAlD
Celecoxib—MAPK14—liver—colon cancer	0.000911	0.0121	CbGeAlD
Celecoxib—PTGS2—gall bladder—colon cancer	0.000893	0.0118	CbGeAlD
Celecoxib—CA14—liver—colon cancer	0.000886	0.0117	CbGeAlD
Celecoxib—CA2—embryo—colon cancer	0.000767	0.0102	CbGeAlD
Celecoxib—ABCC4—renal system—colon cancer	0.000762	0.0101	CbGeAlD
Celecoxib—CA5B—vagina—colon cancer	0.000735	0.00974	CbGeAlD
Celecoxib—CA4—renal system—colon cancer	0.0007	0.00928	CbGeAlD
Celecoxib—MAPK14—lymph node—colon cancer	0.000698	0.00925	CbGeAlD
Celecoxib—ORM1—bone marrow—colon cancer	0.000678	0.00899	CbGeAlD
Celecoxib—CA2—epithelium—colon cancer	0.000626	0.00829	CbGeAlD
Celecoxib—ABCC4—digestive system—colon cancer	0.000625	0.00828	CbGeAlD
Celecoxib—CA2—smooth muscle tissue—colon cancer	0.000603	0.00799	CbGeAlD
Celecoxib—CA2—renal system—colon cancer	0.00058	0.00769	CbGeAlD
Celecoxib—ABCC4—bone marrow—colon cancer	0.000576	0.00763	CbGeAlD
Celecoxib—CA4—digestive system—colon cancer	0.000574	0.00761	CbGeAlD
Celecoxib—PTGS2—embryo—colon cancer	0.000566	0.0075	CbGeAlD
Celecoxib—ORM1—liver—colon cancer	0.000548	0.00727	CbGeAlD
Celecoxib—CA4—bone marrow—colon cancer	0.000529	0.00702	CbGeAlD
Celecoxib—CA2—lymphoid tissue—colon cancer	0.000482	0.00639	CbGeAlD
Celecoxib—ALB—liver—colon cancer	0.000481	0.00637	CbGeAlD
Celecoxib—CA2—digestive system—colon cancer	0.000476	0.00631	CbGeAlD
Celecoxib—CA5B—lymph node—colon cancer	0.000475	0.0063	CbGeAlD
Celecoxib—ABCC4—liver—colon cancer	0.000465	0.00617	CbGeAlD
Celecoxib—PTGS2—epithelium—colon cancer	0.000462	0.00612	CbGeAlD
Celecoxib—PTGS2—smooth muscle tissue—colon cancer	0.000445	0.0059	CbGeAlD
Celecoxib—CA2—bone marrow—colon cancer	0.000439	0.00582	CbGeAlD
Celecoxib—PTGS2—renal system—colon cancer	0.000429	0.00568	CbGeAlD
Celecoxib—CA2—vagina—colon cancer	0.00042	0.00557	CbGeAlD
Celecoxib—ORM1—lymph node—colon cancer	0.00042	0.00557	CbGeAlD
Celecoxib—CYP2C9—digestive system—colon cancer	0.000403	0.00534	CbGeAlD
Celecoxib—CYP3A4—renal system—colon cancer	0.000374	0.00496	CbGeAlD
Celecoxib—ALB—lymph node—colon cancer	0.000369	0.00488	CbGeAlD
Celecoxib—CYP2D6—renal system—colon cancer	0.000369	0.00488	CbGeAlD
Celecoxib—ABCC4—lymph node—colon cancer	0.000357	0.00473	CbGeAlD
Celecoxib—PTGS2—lymphoid tissue—colon cancer	0.000356	0.00472	CbGeAlD
Celecoxib—CA2—liver—colon cancer	0.000355	0.0047	CbGeAlD
Celecoxib—PTGS2—digestive system—colon cancer	0.000351	0.00466	CbGeAlD
Celecoxib—CA4—lymph node—colon cancer	0.000328	0.00435	CbGeAlD
Celecoxib—PTGS2—bone marrow—colon cancer	0.000324	0.00429	CbGeAlD
Celecoxib—PTGS2—vagina—colon cancer	0.00031	0.00411	CbGeAlD
Celecoxib—CYP3A4—digestive system—colon cancer	0.000307	0.00407	CbGeAlD
Celecoxib—CYP2D6—digestive system—colon cancer	0.000302	0.00401	CbGeAlD
Celecoxib—CYP2C9—liver—colon cancer	0.0003	0.00398	CbGeAlD
Celecoxib—CA2—lymph node—colon cancer	0.000272	0.0036	CbGeAlD
Celecoxib—PTGS2—liver—colon cancer	0.000262	0.00347	CbGeAlD
Celecoxib—CYP3A4—liver—colon cancer	0.000229	0.00303	CbGeAlD
Celecoxib—CYP2D6—liver—colon cancer	0.000225	0.00298	CbGeAlD
Celecoxib—PTGS2—lymph node—colon cancer	0.000201	0.00266	CbGeAlD
Celecoxib—Neuropathy peripheral—Capecitabine—colon cancer	0.000194	0.00134	CcSEcCtD
Celecoxib—Myocardial infarction—Capecitabine—colon cancer	0.000194	0.00134	CcSEcCtD
Celecoxib—Anaphylactic shock—Vincristine—colon cancer	0.000194	0.00134	CcSEcCtD
Celecoxib—Oedema—Vincristine—colon cancer	0.000194	0.00134	CcSEcCtD
Celecoxib—Jaundice—Capecitabine—colon cancer	0.000193	0.00133	CcSEcCtD
Celecoxib—Stomatitis—Capecitabine—colon cancer	0.000193	0.00133	CcSEcCtD
Celecoxib—Infection—Vincristine—colon cancer	0.000192	0.00133	CcSEcCtD
Celecoxib—Conjunctivitis—Capecitabine—colon cancer	0.000192	0.00133	CcSEcCtD
Celecoxib—Urinary tract infection—Capecitabine—colon cancer	0.000192	0.00133	CcSEcCtD
Celecoxib—Osteoarthritis—Methotrexate—colon cancer	0.000191	0.00132	CcSEcCtD
Celecoxib—Confusional state—Irinotecan—colon cancer	0.00019	0.00131	CcSEcCtD
Celecoxib—Nervous system disorder—Vincristine—colon cancer	0.00019	0.00131	CcSEcCtD
Celecoxib—Thrombocytopenia—Vincristine—colon cancer	0.00019	0.00131	CcSEcCtD
Celecoxib—Haematuria—Capecitabine—colon cancer	0.000189	0.0013	CcSEcCtD
Celecoxib—Oedema—Irinotecan—colon cancer	0.000189	0.0013	CcSEcCtD
Celecoxib—Anaphylactic shock—Irinotecan—colon cancer	0.000189	0.0013	CcSEcCtD
Celecoxib—Myalgia—Fluorouracil—colon cancer	0.000188	0.0013	CcSEcCtD
Celecoxib—Chest pain—Fluorouracil—colon cancer	0.000188	0.0013	CcSEcCtD
Celecoxib—Infection—Irinotecan—colon cancer	0.000187	0.00129	CcSEcCtD
Celecoxib—Hyperhidrosis—Vincristine—colon cancer	0.000187	0.00129	CcSEcCtD
Celecoxib—Hepatobiliary disease—Capecitabine—colon cancer	0.000187	0.00129	CcSEcCtD
Celecoxib—Epistaxis—Capecitabine—colon cancer	0.000187	0.00129	CcSEcCtD
Celecoxib—Shock—Irinotecan—colon cancer	0.000185	0.00128	CcSEcCtD
Celecoxib—Nervous system disorder—Irinotecan—colon cancer	0.000185	0.00128	CcSEcCtD
Celecoxib—Agranulocytosis—Capecitabine—colon cancer	0.000185	0.00127	CcSEcCtD
Celecoxib—Thrombocytopenia—Irinotecan—colon cancer	0.000185	0.00127	CcSEcCtD
Celecoxib—Anorexia—Vincristine—colon cancer	0.000185	0.00127	CcSEcCtD
Celecoxib—Hyperhidrosis—Irinotecan—colon cancer	0.000182	0.00126	CcSEcCtD
Celecoxib—Confusional state—Fluorouracil—colon cancer	0.000182	0.00126	CcSEcCtD
Celecoxib—Anaphylactic shock—Fluorouracil—colon cancer	0.000181	0.00125	CcSEcCtD
Celecoxib—Oedema—Fluorouracil—colon cancer	0.000181	0.00125	CcSEcCtD
Celecoxib—Anorexia—Irinotecan—colon cancer	0.00018	0.00124	CcSEcCtD
Celecoxib—Ataxia—Methotrexate—colon cancer	0.00018	0.00124	CcSEcCtD
Celecoxib—Infection—Fluorouracil—colon cancer	0.000179	0.00124	CcSEcCtD
Celecoxib—Haemoglobin—Capecitabine—colon cancer	0.000179	0.00123	CcSEcCtD
Celecoxib—Rhinitis—Capecitabine—colon cancer	0.000178	0.00123	CcSEcCtD
Celecoxib—Haemorrhage—Capecitabine—colon cancer	0.000178	0.00123	CcSEcCtD
Celecoxib—Hepatitis—Capecitabine—colon cancer	0.000178	0.00123	CcSEcCtD
Celecoxib—Nervous system disorder—Fluorouracil—colon cancer	0.000177	0.00122	CcSEcCtD
Celecoxib—Thrombocytopenia—Fluorouracil—colon cancer	0.000177	0.00122	CcSEcCtD
Celecoxib—Hypoaesthesia—Capecitabine—colon cancer	0.000177	0.00122	CcSEcCtD
Celecoxib—Liver function test abnormal—Methotrexate—colon cancer	0.000176	0.00122	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000176	0.00122	CcSEcCtD
Celecoxib—Pharyngitis—Capecitabine—colon cancer	0.000176	0.00122	CcSEcCtD
Celecoxib—Tachycardia—Fluorouracil—colon cancer	0.000176	0.00122	CcSEcCtD
Celecoxib—Urinary tract disorder—Capecitabine—colon cancer	0.000175	0.00121	CcSEcCtD
Celecoxib—Insomnia—Vincristine—colon cancer	0.000175	0.00121	CcSEcCtD
Celecoxib—Oedema peripheral—Capecitabine—colon cancer	0.000175	0.00121	CcSEcCtD
Celecoxib—Connective tissue disorder—Capecitabine—colon cancer	0.000175	0.00121	CcSEcCtD
Celecoxib—Urethral disorder—Capecitabine—colon cancer	0.000174	0.0012	CcSEcCtD
Celecoxib—Paraesthesia—Vincristine—colon cancer	0.000174	0.0012	CcSEcCtD
Celecoxib—Breast disorder—Methotrexate—colon cancer	0.000173	0.00119	CcSEcCtD
Celecoxib—Anorexia—Fluorouracil—colon cancer	0.000172	0.00119	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000172	0.00119	CcSEcCtD
Celecoxib—Insomnia—Irinotecan—colon cancer	0.000171	0.00118	CcSEcCtD
Celecoxib—Paraesthesia—Irinotecan—colon cancer	0.000169	0.00117	CcSEcCtD
Celecoxib—Decreased appetite—Vincristine—colon cancer	0.000168	0.00116	CcSEcCtD
Celecoxib—Dyspnoea—Irinotecan—colon cancer	0.000168	0.00116	CcSEcCtD
Celecoxib—Erythema multiforme—Capecitabine—colon cancer	0.000168	0.00116	CcSEcCtD
Celecoxib—Somnolence—Irinotecan—colon cancer	0.000168	0.00116	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Vincristine—colon cancer	0.000167	0.00115	CcSEcCtD
Celecoxib—Fatigue—Vincristine—colon cancer	0.000167	0.00115	CcSEcCtD
Celecoxib—Eye disorder—Capecitabine—colon cancer	0.000166	0.00115	CcSEcCtD
Celecoxib—Dyspepsia—Irinotecan—colon cancer	0.000166	0.00115	CcSEcCtD
Celecoxib—Tinnitus—Capecitabine—colon cancer	0.000166	0.00114	CcSEcCtD
Celecoxib—Constipation—Vincristine—colon cancer	0.000166	0.00114	CcSEcCtD
Celecoxib—Flushing—Capecitabine—colon cancer	0.000165	0.00114	CcSEcCtD
Celecoxib—Cardiac disorder—Capecitabine—colon cancer	0.000165	0.00114	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000165	0.00114	CcSEcCtD
Celecoxib—Decreased appetite—Irinotecan—colon cancer	0.000164	0.00113	CcSEcCtD
Celecoxib—Eosinophilia—Methotrexate—colon cancer	0.000164	0.00113	CcSEcCtD
Celecoxib—Insomnia—Fluorouracil—colon cancer	0.000163	0.00113	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Irinotecan—colon cancer	0.000163	0.00112	CcSEcCtD
Celecoxib—Fatigue—Irinotecan—colon cancer	0.000163	0.00112	CcSEcCtD
Celecoxib—Paraesthesia—Fluorouracil—colon cancer	0.000162	0.00112	CcSEcCtD
Celecoxib—Pancreatitis—Methotrexate—colon cancer	0.000162	0.00112	CcSEcCtD
Celecoxib—Constipation—Irinotecan—colon cancer	0.000161	0.00111	CcSEcCtD
Celecoxib—Angiopathy—Capecitabine—colon cancer	0.000161	0.00111	CcSEcCtD
Celecoxib—Dyspnoea—Fluorouracil—colon cancer	0.000161	0.00111	CcSEcCtD
Celecoxib—Somnolence—Fluorouracil—colon cancer	0.000161	0.00111	CcSEcCtD
Celecoxib—Immune system disorder—Capecitabine—colon cancer	0.00016	0.00111	CcSEcCtD
Celecoxib—Mediastinal disorder—Capecitabine—colon cancer	0.00016	0.00111	CcSEcCtD
Celecoxib—Dyspepsia—Fluorouracil—colon cancer	0.000159	0.0011	CcSEcCtD
Celecoxib—Arrhythmia—Capecitabine—colon cancer	0.000159	0.0011	CcSEcCtD
Celecoxib—Gastrointestinal pain—Vincristine—colon cancer	0.000158	0.00109	CcSEcCtD
Celecoxib—Decreased appetite—Fluorouracil—colon cancer	0.000157	0.00108	CcSEcCtD
Celecoxib—Alopecia—Capecitabine—colon cancer	0.000157	0.00108	CcSEcCtD
Celecoxib—Pancytopenia—Methotrexate—colon cancer	0.000157	0.00108	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000156	0.00108	CcSEcCtD
Celecoxib—Mental disorder—Capecitabine—colon cancer	0.000156	0.00107	CcSEcCtD
Celecoxib—Feeling abnormal—Irinotecan—colon cancer	0.000155	0.00107	CcSEcCtD
Celecoxib—Dysuria—Methotrexate—colon cancer	0.000154	0.00107	CcSEcCtD
Celecoxib—Gastrointestinal pain—Irinotecan—colon cancer	0.000154	0.00106	CcSEcCtD
Celecoxib—Upper respiratory tract infection—Methotrexate—colon cancer	0.000154	0.00106	CcSEcCtD
Celecoxib—Abdominal pain—Vincristine—colon cancer	0.000153	0.00106	CcSEcCtD
Celecoxib—Body temperature increased—Vincristine—colon cancer	0.000153	0.00106	CcSEcCtD
Celecoxib—Flatulence—Capecitabine—colon cancer	0.000152	0.00105	CcSEcCtD
Celecoxib—Dysgeusia—Capecitabine—colon cancer	0.000151	0.00105	CcSEcCtD
Celecoxib—Photosensitivity reaction—Methotrexate—colon cancer	0.000151	0.00104	CcSEcCtD
Celecoxib—Back pain—Capecitabine—colon cancer	0.00015	0.00103	CcSEcCtD
Celecoxib—Abdominal pain—Irinotecan—colon cancer	0.000149	0.00103	CcSEcCtD
Celecoxib—Body temperature increased—Irinotecan—colon cancer	0.000149	0.00103	CcSEcCtD
Celecoxib—Feeling abnormal—Fluorouracil—colon cancer	0.000149	0.00103	CcSEcCtD
Celecoxib—Muscle spasms—Capecitabine—colon cancer	0.000149	0.00103	CcSEcCtD
Celecoxib—Pneumonia—Methotrexate—colon cancer	0.000148	0.00102	CcSEcCtD
Celecoxib—Infestation—Methotrexate—colon cancer	0.000147	0.00102	CcSEcCtD
Celecoxib—Infestation NOS—Methotrexate—colon cancer	0.000147	0.00102	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000146	0.00101	CcSEcCtD
Celecoxib—Vision blurred—Capecitabine—colon cancer	0.000146	0.00101	CcSEcCtD
Celecoxib—Stomatitis—Methotrexate—colon cancer	0.000144	0.000991	CcSEcCtD
Celecoxib—Urticaria—Fluorouracil—colon cancer	0.000143	0.000991	CcSEcCtD
Celecoxib—Conjunctivitis—Methotrexate—colon cancer	0.000143	0.000989	CcSEcCtD
Celecoxib—Anaemia—Capecitabine—colon cancer	0.000143	0.000987	CcSEcCtD
Celecoxib—Body temperature increased—Fluorouracil—colon cancer	0.000143	0.000986	CcSEcCtD
Celecoxib—Hypersensitivity—Vincristine—colon cancer	0.000143	0.000985	CcSEcCtD
Celecoxib—Haematuria—Methotrexate—colon cancer	0.00014	0.00097	CcSEcCtD
Celecoxib—Hepatobiliary disease—Methotrexate—colon cancer	0.000139	0.000962	CcSEcCtD
Celecoxib—Epistaxis—Methotrexate—colon cancer	0.000139	0.000959	CcSEcCtD
Celecoxib—Vertigo—Capecitabine—colon cancer	0.000139	0.000959	CcSEcCtD
Celecoxib—Hypersensitivity—Irinotecan—colon cancer	0.000139	0.000959	CcSEcCtD
Celecoxib—Asthenia—Vincristine—colon cancer	0.000139	0.000959	CcSEcCtD
Celecoxib—Syncope—Capecitabine—colon cancer	0.000139	0.000957	CcSEcCtD
Celecoxib—Leukopenia—Capecitabine—colon cancer	0.000138	0.000956	CcSEcCtD
Celecoxib—Agranulocytosis—Methotrexate—colon cancer	0.000137	0.000949	CcSEcCtD
Celecoxib—Palpitations—Capecitabine—colon cancer	0.000137	0.000943	CcSEcCtD
Celecoxib—Loss of consciousness—Capecitabine—colon cancer	0.000136	0.000938	CcSEcCtD
Celecoxib—Asthenia—Irinotecan—colon cancer	0.000135	0.000934	CcSEcCtD
Celecoxib—Cough—Capecitabine—colon cancer	0.000135	0.000932	CcSEcCtD
Celecoxib—Hypertension—Capecitabine—colon cancer	0.000133	0.000922	CcSEcCtD
Celecoxib—Hypersensitivity—Fluorouracil—colon cancer	0.000133	0.000919	CcSEcCtD
Celecoxib—Haemoglobin—Methotrexate—colon cancer	0.000133	0.000918	CcSEcCtD
Celecoxib—Diarrhoea—Vincristine—colon cancer	0.000132	0.000915	CcSEcCtD
Celecoxib—Hepatitis—Methotrexate—colon cancer	0.000132	0.000913	CcSEcCtD
Celecoxib—Haemorrhage—Methotrexate—colon cancer	0.000132	0.000913	CcSEcCtD
Celecoxib—Chest pain—Capecitabine—colon cancer	0.000132	0.000909	CcSEcCtD
Celecoxib—Arthralgia—Capecitabine—colon cancer	0.000132	0.000909	CcSEcCtD
Celecoxib—Myalgia—Capecitabine—colon cancer	0.000132	0.000909	CcSEcCtD
Celecoxib—Pharyngitis—Methotrexate—colon cancer	0.000131	0.000906	CcSEcCtD
Celecoxib—Anxiety—Capecitabine—colon cancer	0.000131	0.000906	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000131	0.000903	CcSEcCtD
Celecoxib—Urinary tract disorder—Methotrexate—colon cancer	0.000131	0.000902	CcSEcCtD
Celecoxib—Urethral disorder—Methotrexate—colon cancer	0.00013	0.000895	CcSEcCtD
Celecoxib—Diarrhoea—Irinotecan—colon cancer	0.000129	0.000891	CcSEcCtD
Celecoxib—Dry mouth—Capecitabine—colon cancer	0.000129	0.000889	CcSEcCtD
Celecoxib—Dizziness—Vincristine—colon cancer	0.000128	0.000884	CcSEcCtD
Celecoxib—Pruritus—Fluorouracil—colon cancer	0.000128	0.000882	CcSEcCtD
Celecoxib—Confusional state—Capecitabine—colon cancer	0.000127	0.000879	CcSEcCtD
Celecoxib—Oedema—Capecitabine—colon cancer	0.000126	0.000871	CcSEcCtD
Celecoxib—Infection—Capecitabine—colon cancer	0.000125	0.000866	CcSEcCtD
Celecoxib—Erythema multiforme—Methotrexate—colon cancer	0.000125	0.000863	CcSEcCtD
Celecoxib—Dizziness—Irinotecan—colon cancer	0.000125	0.000861	CcSEcCtD
Celecoxib—Shock—Capecitabine—colon cancer	0.000124	0.000857	CcSEcCtD
Celecoxib—Nervous system disorder—Capecitabine—colon cancer	0.000124	0.000854	CcSEcCtD
Celecoxib—Eye disorder—Methotrexate—colon cancer	0.000124	0.000853	CcSEcCtD
Celecoxib—Diarrhoea—Fluorouracil—colon cancer	0.000124	0.000853	CcSEcCtD
Celecoxib—Thrombocytopenia—Capecitabine—colon cancer	0.000124	0.000853	CcSEcCtD
Celecoxib—Tinnitus—Methotrexate—colon cancer	0.000123	0.000851	CcSEcCtD
Celecoxib—Tachycardia—Capecitabine—colon cancer	0.000123	0.00085	CcSEcCtD
Celecoxib—Vomiting—Vincristine—colon cancer	0.000123	0.00085	CcSEcCtD
Celecoxib—Cardiac disorder—Methotrexate—colon cancer	0.000123	0.000847	CcSEcCtD
Celecoxib—Skin disorder—Capecitabine—colon cancer	0.000123	0.000846	CcSEcCtD
Celecoxib—Rash—Vincristine—colon cancer	0.000122	0.000843	CcSEcCtD
Celecoxib—Hyperhidrosis—Capecitabine—colon cancer	0.000122	0.000842	CcSEcCtD
Celecoxib—Dermatitis—Vincristine—colon cancer	0.000122	0.000842	CcSEcCtD
Celecoxib—Headache—Vincristine—colon cancer	0.000121	0.000837	CcSEcCtD
Celecoxib—Anorexia—Capecitabine—colon cancer	0.00012	0.000831	CcSEcCtD
Celecoxib—Angiopathy—Methotrexate—colon cancer	0.00012	0.000828	CcSEcCtD
Celecoxib—Vomiting—Irinotecan—colon cancer	0.00012	0.000828	CcSEcCtD
Celecoxib—Immune system disorder—Methotrexate—colon cancer	0.000119	0.000825	CcSEcCtD
Celecoxib—Dizziness—Fluorouracil—colon cancer	0.000119	0.000825	CcSEcCtD
Celecoxib—Mediastinal disorder—Methotrexate—colon cancer	0.000119	0.000823	CcSEcCtD
Celecoxib—Rash—Irinotecan—colon cancer	0.000119	0.000821	CcSEcCtD
Celecoxib—Dermatitis—Irinotecan—colon cancer	0.000119	0.00082	CcSEcCtD
Celecoxib—Headache—Irinotecan—colon cancer	0.000118	0.000816	CcSEcCtD
Celecoxib—Alopecia—Methotrexate—colon cancer	0.000117	0.000807	CcSEcCtD
Celecoxib—Mental disorder—Methotrexate—colon cancer	0.000116	0.0008	CcSEcCtD
Celecoxib—Nausea—Vincristine—colon cancer	0.000115	0.000794	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000115	0.000794	CcSEcCtD
Celecoxib—Vomiting—Fluorouracil—colon cancer	0.000115	0.000793	CcSEcCtD
Celecoxib—Insomnia—Capecitabine—colon cancer	0.000114	0.000788	CcSEcCtD
Celecoxib—Rash—Fluorouracil—colon cancer	0.000114	0.000786	CcSEcCtD
Celecoxib—Dermatitis—Fluorouracil—colon cancer	0.000114	0.000785	CcSEcCtD
Celecoxib—Paraesthesia—Capecitabine—colon cancer	0.000113	0.000782	CcSEcCtD
Celecoxib—Headache—Fluorouracil—colon cancer	0.000113	0.000781	CcSEcCtD
Celecoxib—Dysgeusia—Methotrexate—colon cancer	0.000113	0.000778	CcSEcCtD
Celecoxib—Dyspnoea—Capecitabine—colon cancer	0.000113	0.000777	CcSEcCtD
Celecoxib—Nausea—Irinotecan—colon cancer	0.000112	0.000773	CcSEcCtD
Celecoxib—Back pain—Methotrexate—colon cancer	0.000111	0.000769	CcSEcCtD
Celecoxib—Dyspepsia—Capecitabine—colon cancer	0.000111	0.000767	CcSEcCtD
Celecoxib—Decreased appetite—Capecitabine—colon cancer	0.00011	0.000757	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Capecitabine—colon cancer	0.000109	0.000752	CcSEcCtD
Celecoxib—Fatigue—Capecitabine—colon cancer	0.000109	0.000751	CcSEcCtD
Celecoxib—Vision blurred—Methotrexate—colon cancer	0.000108	0.000749	CcSEcCtD
Celecoxib—Constipation—Capecitabine—colon cancer	0.000108	0.000745	CcSEcCtD
Celecoxib—Nausea—Fluorouracil—colon cancer	0.000107	0.000741	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—colon cancer	0.000106	0.000735	CcSEcCtD
Celecoxib—Feeling abnormal—Capecitabine—colon cancer	0.000104	0.000718	CcSEcCtD
Celecoxib—Vertigo—Methotrexate—colon cancer	0.000103	0.000714	CcSEcCtD
Celecoxib—Gastrointestinal pain—Capecitabine—colon cancer	0.000103	0.000712	CcSEcCtD
Celecoxib—Leukopenia—Methotrexate—colon cancer	0.000103	0.000711	CcSEcCtD
Celecoxib—Cough—Methotrexate—colon cancer	0.0001	0.000694	CcSEcCtD
Celecoxib—Urticaria—Capecitabine—colon cancer	0.0001	0.000692	CcSEcCtD
Celecoxib—Abdominal pain—Capecitabine—colon cancer	9.98e-05	0.000689	CcSEcCtD
Celecoxib—Body temperature increased—Capecitabine—colon cancer	9.98e-05	0.000689	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—colon cancer	9.8e-05	0.000677	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—colon cancer	9.8e-05	0.000677	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—colon cancer	9.8e-05	0.000677	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	9.73e-05	0.000672	CcSEcCtD
Celecoxib—Confusional state—Methotrexate—colon cancer	9.47e-05	0.000654	CcSEcCtD
Celecoxib—Anaphylactic shock—Methotrexate—colon cancer	9.39e-05	0.000649	CcSEcCtD
Celecoxib—Infection—Methotrexate—colon cancer	9.33e-05	0.000644	CcSEcCtD
Celecoxib—Hypersensitivity—Capecitabine—colon cancer	9.3e-05	0.000642	CcSEcCtD
Celecoxib—Nervous system disorder—Methotrexate—colon cancer	9.21e-05	0.000636	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—colon cancer	9.2e-05	0.000635	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—colon cancer	9.12e-05	0.00063	CcSEcCtD
Celecoxib—Hyperhidrosis—Methotrexate—colon cancer	9.08e-05	0.000627	CcSEcCtD
Celecoxib—Asthenia—Capecitabine—colon cancer	9.05e-05	0.000625	CcSEcCtD
Celecoxib—Anorexia—Methotrexate—colon cancer	8.95e-05	0.000618	CcSEcCtD
Celecoxib—Pruritus—Capecitabine—colon cancer	8.93e-05	0.000616	CcSEcCtD
Celecoxib—Diarrhoea—Capecitabine—colon cancer	8.63e-05	0.000596	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methotrexate—colon cancer	8.56e-05	0.000591	CcSEcCtD
Celecoxib—Insomnia—Methotrexate—colon cancer	8.5e-05	0.000587	CcSEcCtD
Celecoxib—Paraesthesia—Methotrexate—colon cancer	8.44e-05	0.000582	CcSEcCtD
Celecoxib—Dyspnoea—Methotrexate—colon cancer	8.38e-05	0.000578	CcSEcCtD
Celecoxib—Somnolence—Methotrexate—colon cancer	8.35e-05	0.000577	CcSEcCtD
Celecoxib—Dizziness—Capecitabine—colon cancer	8.34e-05	0.000576	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—colon cancer	8.27e-05	0.000571	CcSEcCtD
Celecoxib—Decreased appetite—Methotrexate—colon cancer	8.17e-05	0.000564	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Methotrexate—colon cancer	8.11e-05	0.00056	CcSEcCtD
Celecoxib—Fatigue—Methotrexate—colon cancer	8.1e-05	0.000559	CcSEcCtD
Celecoxib—Vomiting—Capecitabine—colon cancer	8.02e-05	0.000554	CcSEcCtD
Celecoxib—Rash—Capecitabine—colon cancer	7.96e-05	0.000549	CcSEcCtD
Celecoxib—Dermatitis—Capecitabine—colon cancer	7.95e-05	0.000549	CcSEcCtD
Celecoxib—Headache—Capecitabine—colon cancer	7.91e-05	0.000546	CcSEcCtD
Celecoxib—Feeling abnormal—Methotrexate—colon cancer	7.74e-05	0.000535	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methotrexate—colon cancer	7.68e-05	0.00053	CcSEcCtD
Celecoxib—Nausea—Capecitabine—colon cancer	7.5e-05	0.000518	CcSEcCtD
Celecoxib—Urticaria—Methotrexate—colon cancer	7.46e-05	0.000515	CcSEcCtD
Celecoxib—Abdominal pain—Methotrexate—colon cancer	7.43e-05	0.000513	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—colon cancer	7.43e-05	0.000513	CcSEcCtD
Celecoxib—Hypersensitivity—Methotrexate—colon cancer	6.92e-05	0.000478	CcSEcCtD
Celecoxib—Asthenia—Methotrexate—colon cancer	6.74e-05	0.000465	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—colon cancer	6.65e-05	0.000459	CcSEcCtD
Celecoxib—Diarrhoea—Methotrexate—colon cancer	6.43e-05	0.000444	CcSEcCtD
Celecoxib—Dizziness—Methotrexate—colon cancer	6.21e-05	0.000429	CcSEcCtD
Celecoxib—Vomiting—Methotrexate—colon cancer	5.97e-05	0.000412	CcSEcCtD
Celecoxib—Rash—Methotrexate—colon cancer	5.92e-05	0.000409	CcSEcCtD
Celecoxib—Dermatitis—Methotrexate—colon cancer	5.92e-05	0.000409	CcSEcCtD
Celecoxib—Headache—Methotrexate—colon cancer	5.88e-05	0.000406	CcSEcCtD
Celecoxib—Nausea—Methotrexate—colon cancer	5.58e-05	0.000385	CcSEcCtD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.83e-05	9.67e-05	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.82e-05	9.65e-05	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—EP300—colon cancer	1.82e-05	9.61e-05	CbGpPWpGaD
Celecoxib—CA6—Metabolism—EP300—colon cancer	1.82e-05	9.61e-05	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—TP53—colon cancer	1.81e-05	9.6e-05	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.79e-05	9.46e-05	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—HRAS—colon cancer	1.79e-05	9.45e-05	CbGpPWpGaD
Celecoxib—MAPK14—Metabolism of mRNA—AKT1—colon cancer	1.78e-05	9.41e-05	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—AKT1—colon cancer	1.77e-05	9.34e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—PIK3CA—colon cancer	1.76e-05	9.31e-05	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—AKT1—colon cancer	1.75e-05	9.27e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—EP300—colon cancer	1.72e-05	9.1e-05	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—HRAS—colon cancer	1.72e-05	9.08e-05	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—EP300—colon cancer	1.7e-05	8.97e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—FGFR3—colon cancer	1.7e-05	8.97e-05	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.69e-05	8.94e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PTGS2—colon cancer	1.69e-05	8.93e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—SRC—colon cancer	1.67e-05	8.85e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD8A—colon cancer	1.67e-05	8.81e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—CTNNB1—colon cancer	1.65e-05	8.74e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CTNNB1—colon cancer	1.64e-05	8.65e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—VEGFA—colon cancer	1.63e-05	8.62e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—HRAS—colon cancer	1.63e-05	8.61e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—NRAS—colon cancer	1.61e-05	8.52e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CDKN1A—colon cancer	1.6e-05	8.45e-05	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—AKT1—colon cancer	1.58e-05	8.35e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—EP300—colon cancer	1.57e-05	8.31e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—APC—colon cancer	1.56e-05	8.24e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—NRAS—colon cancer	1.56e-05	8.24e-05	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.55e-05	8.21e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PPARG—colon cancer	1.55e-05	8.19e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—EP300—colon cancer	1.54e-05	8.13e-05	CbGpPWpGaD
Celecoxib—MAPK14—Metabolism of RNA—AKT1—colon cancer	1.52e-05	8.06e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—EP300—colon cancer	1.52e-05	8.04e-05	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—AKT1—colon cancer	1.51e-05	8.01e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CTNNB1—colon cancer	1.51e-05	7.99e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—EP300—colon cancer	1.51e-05	7.97e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PTGS2—colon cancer	1.51e-05	7.97e-05	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.5e-05	7.94e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TGFB1—colon cancer	1.5e-05	7.91e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—SRC—colon cancer	1.49e-05	7.9e-05	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	1.48e-05	7.83e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—SRC—colon cancer	1.48e-05	7.82e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CDKN1A—colon cancer	1.48e-05	7.8e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	1.47e-05	7.77e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—SRC—colon cancer	1.47e-05	7.75e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—BRAF—colon cancer	1.46e-05	7.74e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CTNNB1—colon cancer	1.46e-05	7.72e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—VEGFA—colon cancer	1.45e-05	7.7e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PTGS2—colon cancer	1.44e-05	7.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—AKT1—colon cancer	1.44e-05	7.6e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—NRAS—colon cancer	1.44e-05	7.6e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	1.43e-05	7.57e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—VEGFA—colon cancer	1.43e-05	7.55e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CDKN1A—colon cancer	1.43e-05	7.54e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—BCL2L1—colon cancer	1.43e-05	7.54e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—NRAS—colon cancer	1.42e-05	7.52e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—EGFR—colon cancer	1.42e-05	7.5e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CHST5—colon cancer	1.42e-05	7.5e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ODC1—colon cancer	1.42e-05	7.5e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—NRAS—colon cancer	1.41e-05	7.46e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—EP300—colon cancer	1.4e-05	7.43e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—KRAS—colon cancer	1.39e-05	7.33e-05	CbGpPWpGaD
Celecoxib—CA14—Metabolism—PIK3CA—colon cancer	1.38e-05	7.3e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—SRC—colon cancer	1.37e-05	7.22e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—FGFR3—colon cancer	1.36e-05	7.21e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—EP300—colon cancer	1.36e-05	7.18e-05	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—PIK3CA—colon cancer	1.36e-05	7.17e-05	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—PIK3CA—colon cancer	1.34e-05	7.11e-05	CbGpPWpGaD
Celecoxib—CA6—Metabolism—PIK3CA—colon cancer	1.34e-05	7.11e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—KRAS—colon cancer	1.34e-05	7.09e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.34e-05	7.09e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TGFB1—colon cancer	1.34e-05	7.06e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—SRC—colon cancer	1.32e-05	6.98e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	1.31e-05	6.95e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—NRAS—colon cancer	1.31e-05	6.95e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TGFB1—colon cancer	1.31e-05	6.93e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—EGFR—colon cancer	1.31e-05	6.93e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—EGFR—colon cancer	1.3e-05	6.86e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—PIK3CA—colon cancer	1.27e-05	6.73e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—NRAS—colon cancer	1.27e-05	6.71e-05	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.27e-05	6.71e-05	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—PIK3CA—colon cancer	1.25e-05	6.64e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—EP300—colon cancer	1.25e-05	6.63e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—KRAS—colon cancer	1.24e-05	6.54e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TP53—colon cancer	1.23e-05	6.52e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—PIK3CA—colon cancer	1.23e-05	6.51e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—KRAS—colon cancer	1.22e-05	6.48e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—MYC—colon cancer	1.22e-05	6.47e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—TGFB1—colon cancer	1.22e-05	6.46e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTGS2—colon cancer	1.22e-05	6.44e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—KRAS—colon cancer	1.21e-05	6.42e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—EP300—colon cancer	1.2e-05	6.36e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—PPARG—colon cancer	1.2e-05	6.35e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—EGFR—colon cancer	1.2e-05	6.33e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—HRAS—colon cancer	1.18e-05	6.23e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—PIK3CA—colon cancer	1.16e-05	6.15e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—EGFR—colon cancer	1.16e-05	6.12e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDH1—colon cancer	1.15e-05	6.09e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—HRAS—colon cancer	1.14e-05	6.02e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—KRAS—colon cancer	1.13e-05	5.98e-05	CbGpPWpGaD
Celecoxib—CA14—Metabolism—AKT1—colon cancer	1.13e-05	5.96e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—PIK3CA—colon cancer	1.12e-05	5.95e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	1.12e-05	5.91e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—PIK3CA—colon cancer	1.11e-05	5.9e-05	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—AKT1—colon cancer	1.11e-05	5.86e-05	CbGpPWpGaD
Celecoxib—CA6—Metabolism—AKT1—colon cancer	1.1e-05	5.81e-05	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—AKT1—colon cancer	1.1e-05	5.81e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CASP3—colon cancer	1.1e-05	5.8e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—KRAS—colon cancer	1.09e-05	5.78e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.08e-05	5.73e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TP53—colon cancer	1.08e-05	5.7e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCND1—colon cancer	1.07e-05	5.65e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CTNNB1—colon cancer	1.06e-05	5.59e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—HRAS—colon cancer	1.05e-05	5.56e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HRAS—colon cancer	1.04e-05	5.5e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—AKT1—colon cancer	1.04e-05	5.5e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PIK3CA—colon cancer	1.04e-05	5.49e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CDKN1A—colon cancer	1.03e-05	5.47e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—HRAS—colon cancer	1.03e-05	5.46e-05	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—AKT1—colon cancer	1.02e-05	5.42e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—EP300—colon cancer	1.01e-05	5.36e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—AKT1—colon cancer	1.01e-05	5.32e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—PIK3CA—colon cancer	1e-05	5.31e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—EP300—colon cancer	9.83e-06	5.2e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—HRAS—colon cancer	9.61e-06	5.08e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—SRC—colon cancer	9.56e-06	5.06e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—AKT1—colon cancer	9.5e-06	5.02e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—VEGFA—colon cancer	9.31e-06	4.93e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HRAS—colon cancer	9.28e-06	4.91e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—AKT1—colon cancer	9.28e-06	4.91e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PIK3CA—colon cancer	9.27e-06	4.9e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—NRAS—colon cancer	9.2e-06	4.86e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—AKT1—colon cancer	9.19e-06	4.86e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	9.13e-06	4.83e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—AKT1—colon cancer	9.11e-06	4.82e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PIK3CA—colon cancer	8.89e-06	4.7e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	8.87e-06	4.69e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FGFR3—colon cancer	8.81e-06	4.66e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	8.76e-06	4.64e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ABCB1—colon cancer	8.57e-06	4.54e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MYC—colon cancer	8.57e-06	4.53e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TGFB1—colon cancer	8.55e-06	4.52e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.53e-06	4.51e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CTNNB1—colon cancer	8.5e-06	4.5e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—AKT1—colon cancer	8.48e-06	4.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—TYMS—colon cancer	8.42e-06	4.45e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—EGFR—colon cancer	8.38e-06	4.43e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDKN1A—colon cancer	8.3e-06	4.39e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—AKT1—colon cancer	8.2e-06	4.34e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—APC—colon cancer	8.09e-06	4.28e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FGFR3—colon cancer	8.04e-06	4.25e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KRAS—colon cancer	7.92e-06	4.19e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EP300—colon cancer	7.9e-06	4.18e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—EP300—colon cancer	7.79e-06	4.12e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—SRC—colon cancer	7.68e-06	4.06e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—BRAF—colon cancer	7.6e-06	4.02e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—SRC—colon cancer	7.57e-06	4.01e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—AKT1—colon cancer	7.57e-06	4.01e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PIK3CA—colon cancer	7.49e-06	3.96e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NRAS—colon cancer	7.39e-06	3.91e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—APC—colon cancer	7.38e-06	3.9e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—VEGFA—colon cancer	7.38e-06	3.9e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NRAS—colon cancer	7.29e-06	3.85e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PIK3CA—colon cancer	7.27e-06	3.85e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—AKT1—colon cancer	7.26e-06	3.84e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.09e-06	3.75e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—colon cancer	7.03e-06	3.72e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.98e-06	3.69e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—BRAF—colon cancer	6.94e-06	3.67e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ABCB1—colon cancer	6.94e-06	3.67e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MYC—colon cancer	6.85e-06	3.62e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—TYMS—colon cancer	6.81e-06	3.6e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TGFB1—colon cancer	6.77e-06	3.58e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EGFR—colon cancer	6.73e-06	3.56e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—HRAS—colon cancer	6.73e-06	3.56e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.48e-06	3.43e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KRAS—colon cancer	6.36e-06	3.37e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—KRAS—colon cancer	6.27e-06	3.32e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—AKT1—colon cancer	6.12e-06	3.24e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PPARG—colon cancer	5.97e-06	3.16e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—AKT1—colon cancer	5.94e-06	3.14e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CA—colon cancer	5.84e-06	3.09e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.8e-06	3.07e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CA—colon cancer	5.76e-06	3.05e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ABCB1—colon cancer	5.73e-06	3.03e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CASP3—colon cancer	5.7e-06	3.02e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ABCB1—colon cancer	5.68e-06	3e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—TYMS—colon cancer	5.63e-06	2.98e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—TYMS—colon cancer	5.58e-06	2.95e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—colon cancer	5.57e-06	2.95e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCND1—colon cancer	5.55e-06	2.94e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CTNNB1—colon cancer	5.5e-06	2.91e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HRAS—colon cancer	5.41e-06	2.86e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1A—colon cancer	5.37e-06	2.84e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—HRAS—colon cancer	5.33e-06	2.82e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.25e-06	2.77e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EP300—colon cancer	5.11e-06	2.7e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CTNNB1—colon cancer	5.01e-06	2.65e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SRC—colon cancer	4.97e-06	2.63e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1A—colon cancer	4.9e-06	2.59e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—VEGFA—colon cancer	4.84e-06	2.56e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PPARG—colon cancer	4.83e-06	2.55e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NRAS—colon cancer	4.78e-06	2.53e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—AKT1—colon cancer	4.77e-06	2.53e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—AKT1—colon cancer	4.75e-06	2.51e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—AKT1—colon cancer	4.71e-06	2.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EP300—colon cancer	4.66e-06	2.47e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SRC—colon cancer	4.53e-06	2.4e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MYC—colon cancer	4.45e-06	2.35e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TGFB1—colon cancer	4.44e-06	2.35e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NRAS—colon cancer	4.36e-06	2.31e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EGFR—colon cancer	4.35e-06	2.3e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.29e-06	2.27e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KRAS—colon cancer	4.11e-06	2.18e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MYC—colon cancer	4.06e-06	2.15e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TGFB1—colon cancer	4.05e-06	2.14e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PPARG—colon cancer	3.98e-06	2.11e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EGFR—colon cancer	3.97e-06	2.1e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PPARG—colon cancer	3.95e-06	2.09e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—EP300—colon cancer	3.9e-06	2.06e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS2—colon cancer	3.8e-06	2.01e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CA—colon cancer	3.78e-06	2e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KRAS—colon cancer	3.75e-06	1.98e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ABCB1—colon cancer	3.74e-06	1.98e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—TYMS—colon cancer	3.68e-06	1.95e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—colon cancer	3.66e-06	1.93e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HRAS—colon cancer	3.5e-06	1.85e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CA—colon cancer	3.45e-06	1.82e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HRAS—colon cancer	3.19e-06	1.69e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—EP300—colon cancer	3.16e-06	1.67e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS2—colon cancer	3.13e-06	1.66e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS2—colon cancer	3.11e-06	1.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—AKT1—colon cancer	3.09e-06	1.63e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CA—colon cancer	2.89e-06	1.53e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—AKT1—colon cancer	2.82e-06	1.49e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—EP300—colon cancer	2.61e-06	1.38e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PPARG—colon cancer	2.61e-06	1.38e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—EP300—colon cancer	2.58e-06	1.37e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—AKT1—colon cancer	2.36e-06	1.25e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CA—colon cancer	2.34e-06	1.24e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS2—colon cancer	2.05e-06	1.08e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CA—colon cancer	1.93e-06	1.02e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CA—colon cancer	1.91e-06	1.01e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—AKT1—colon cancer	1.91e-06	1.01e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—EP300—colon cancer	1.7e-06	9.02e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AKT1—colon cancer	1.58e-06	8.33e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AKT1—colon cancer	1.56e-06	8.26e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CA—colon cancer	1.26e-06	6.67e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AKT1—colon cancer	1.03e-06	5.45e-06	CbGpPWpGaD
